FR17C1062I1 - - Google Patents

Info

Publication number
FR17C1062I1
FR17C1062I1 FR17C1062C FR17C1062I1 FR 17C1062 I1 FR17C1062 I1 FR 17C1062I1 FR 17C1062 C FR17C1062 C FR 17C1062C FR 17C1062 I1 FR17C1062 I1 FR 17C1062I1
Authority
FR
France
Prior art keywords
disclosed
antibody
cdr
antibody molecules
cdrs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9935990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR17C1062(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR17C1062I1 publication Critical patent/FR17C1062I1/fr
Application granted granted Critical
Publication of FR17C1062I2 publication Critical patent/FR17C1062I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR17C1062C 2002-05-02 2017-12-21 Anticorps specifiques a l' humain cd22 et leurs utilisation therapeutiques et diagnostiques Active FR17C1062I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0210121.0A GB0210121D0 (en) 2002-05-02 2002-05-02 Biological products
PCT/GB2003/001934 WO2003093320A2 (en) 2002-05-02 2003-05-02 Antibodies specific for human cd22 and their therapeuatic and digagnostic uses

Publications (2)

Publication Number Publication Date
FR17C1062I1 true FR17C1062I1 (ja) 2018-02-16
FR17C1062I2 FR17C1062I2 (fr) 2020-05-29

Family

ID=9935990

Family Applications (1)

Application Number Title Priority Date Filing Date
FR17C1062C Active FR17C1062I2 (fr) 2002-05-02 2017-12-21 Anticorps specifiques a l' humain cd22 et leurs utilisation therapeutiques et diagnostiques

Country Status (35)

Country Link
US (8) US7355011B2 (ja)
EP (1) EP1504035B9 (ja)
JP (3) JP4486494B2 (ja)
KR (3) KR101386376B1 (ja)
CN (3) CN100384878C (ja)
AT (1) ATE462729T3 (ja)
AU (1) AU2003223007C1 (ja)
BE (1) BE2017C068I2 (ja)
CA (1) CA2484420C (ja)
CO (1) CO5631451A2 (ja)
CY (3) CY1110134T1 (ja)
DE (1) DE60331910D1 (ja)
DK (1) DK1504035T6 (ja)
EC (1) ECSP045470A (ja)
ES (1) ES2341708T7 (ja)
FR (1) FR17C1062I2 (ja)
GB (1) GB0210121D0 (ja)
HK (2) HK1071762A1 (ja)
HU (2) HUS1700055I1 (ja)
IL (1) IL164923A (ja)
LT (2) LTPA2017043I1 (ja)
LU (2) LUC00057I2 (ja)
MX (1) MXPA04010787A (ja)
NL (1) NL300920I2 (ja)
NO (3) NO336201B3 (ja)
NZ (1) NZ536757A (ja)
PL (1) PL218433B1 (ja)
PT (1) PT1504035E (ja)
RU (1) RU2342401C2 (ja)
SG (1) SG161744A1 (ja)
SI (1) SI1504035T1 (ja)
TW (1) TWI324161B (ja)
UA (1) UA92580C2 (ja)
WO (1) WO2003093320A2 (ja)
ZA (1) ZA200408851B (ja)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE468348T1 (de) 2001-09-26 2010-06-15 Government Of The Us Secretary Mutierte anti-cd22-antikörper mit erhöhter affinität zu cd22-exprimierenden leukämiezellen
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
AU2003224624B2 (en) 2002-02-21 2008-08-28 Duke University Reagents and treatment methods for autoimmune diseases
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
ES2916174T3 (es) 2002-05-02 2022-06-28 Wyeth Holdings Llc Conjugados de transportador derivado de caliqueamicina
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GT200500283A (es) * 2004-10-08 2006-05-08 Inmunoterapia de desordenes autoinmunes
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
EP1998799B8 (en) * 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP1999148B8 (en) * 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
TWI523864B (zh) * 2006-05-30 2016-03-01 建南德克公司 抗體及免疫接合物及其用途
US8481683B2 (en) 2006-12-01 2013-07-09 Medarex, Inc. Human antibodies that bind CD22 and uses thereof
US8591889B2 (en) 2008-04-04 2013-11-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies specific for CD22
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US9238878B2 (en) * 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
EP2473637B1 (en) 2009-09-03 2017-03-29 F. Hoffmann-La Roche AG Methods for treating, diagnosing, and monitoring rheumatoid arthritis
CN103415621A (zh) 2011-01-14 2013-11-27 雷德伍德生物科技股份有限公司 醛标记免疫球蛋白多肽及其使用方法
JP6271254B2 (ja) 2011-02-28 2018-01-31 ジェネンテック， インコーポレイテッド Ｂ細胞アンタゴニストに対する生物学的マーカー及び応答を予測するための方法
KR20150008080A (ko) 2012-04-26 2015-01-21 바이오아트라, 엘엘씨 항-cd22 항체
SG11201408626YA (en) 2012-07-03 2015-03-30 Univ Washington Antibodies to tau
IN2015DN00552A (ja) 2012-07-19 2015-06-26 Redwood Bioscience Inc
BR112015009003B1 (pt) 2012-10-24 2023-01-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Receptores de antígeno quiméricos que se ligam especificamente a cd22, ácido nucleico, vetor de expressão recombinante, microrganismo transgênico, composição farmacêutica, e uso dos mesmos
CN103214578B (zh) * 2013-05-10 2014-05-28 北京东方百泰生物科技有限公司 一种新型的人源化抗cd22抗体
CN105828841A (zh) 2013-11-04 2016-08-03 辉瑞大药厂 抗-efna4抗体-药物缀合物
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
ES2923894T3 (es) * 2015-04-08 2022-10-03 Novartis Ag Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
KR20180102065A (ko) 2015-11-09 2018-09-14 알.피.쉐러 테크놀러지즈 엘엘씨 항-cd22 항체-메이탄신 콘쥬게이트 및 그것의 사용 방법
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
CN109071634A (zh) 2016-04-26 2018-12-21 R.P.谢勒技术有限责任公司 抗体偶联物及其制备和使用方法
GB201610512D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
SG11201903521XA (en) 2016-10-21 2019-05-30 Amgen Inc Pharmaceutical formulations and methods of making the same
CA3095595A1 (en) 2018-03-30 2019-10-03 Eureka Therapeutics, Inc. Constructs targeting cd22 and uses thereof
WO2021197483A1 (zh) * 2020-04-02 2021-10-07 南京驯鹿医疗技术有限公司 全人源抗人cd22的嵌合抗原受体及其应用
US20230331840A1 (en) * 2020-08-27 2023-10-19 Fapon Biotherapy Inc. Cd22 antibody and application thereof
WO2022262783A1 (zh) * 2021-06-16 2022-12-22 西安宇繁生物科技有限责任公司 抗cd22的全人源抗体或其抗原结合片段及其制备方法和应用
JP2024534148A (ja) * 2021-08-27 2024-09-18 ペプトロン インコーポレイテッド 新規抗ｍｕｃ１抗体およびその用途
US20240166705A1 (en) 2022-11-07 2024-05-23 Xencor, Inc. Il18-fc fusion proteins

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957362A (en) * 1972-10-02 1976-05-18 Corneal Sciences, Inc. Hydrogels and articles made therefrom
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5134075A (en) * 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE207075T1 (de) * 1990-06-27 2001-11-15 Univ Princeton Sonden für die detektion der p53 mutante
DK0531472T3 (da) * 1991-03-06 2003-12-01 Merck Patent Gmbh Humaniserede monoklonale antistoffer
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5714340A (en) * 1992-12-22 1998-02-03 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassay elements having a receptor zone
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
ES2270425T3 (es) * 1994-01-25 2007-04-01 Elan Pharmaceuticals, Inc. Anticuerpos humanizados contra la molecula de adhesion leucocitaria vla-4.
JP3053873B2 (ja) * 1994-08-12 2000-06-19 イムノメディクス，インコーポレイテッド Ｂ細胞リンパ腫細胞および白血病細胞に特異的な免疫結合体およびヒト化抗体
ES2158048T5 (es) 1994-08-12 2009-11-04 The University Of Utah Research Foundation Mutaciones del gen ligado al cromosoma 17q, de susceptibilidad al cancer de mama y de ovario.
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) * 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20020141990A1 (en) * 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
EP0977590A4 (en) * 1996-11-01 2001-03-14 Smithkline Beecham Corp HUMAN MONOCLONAL ANTIBODIES
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
ATE383430T1 (de) 1997-03-20 2008-01-15 Us Gov Health & Human Serv Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
DK0999853T3 (da) 1997-06-13 2003-04-22 Genentech Inc Stabiliseret antostofformulering
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
KR100345463B1 (ko) * 1998-11-19 2003-01-08 주)녹십자 B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
EP2289551A1 (en) * 1999-06-09 2011-03-02 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target B-cells
CN1382259A (zh) * 1999-10-12 2002-11-27 康奈科斯优化研究和发展有限公司 检测粪便中抗酸微生物的改进方法
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
SG136804A1 (en) * 2000-07-12 2007-11-29 Idec Pharma Corp Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
CN1205479C (zh) * 2000-10-31 2005-06-08 杨梦甦 免疫学诊断蛋白芯片制备方法
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
ES2916174T3 (es) 2002-05-02 2022-06-28 Wyeth Holdings Llc Conjugados de transportador derivado de caliqueamicina
EP1999148B8 (en) * 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease

Also Published As

Publication number Publication date
WO2003093320A3 (en) 2004-02-05
KR20050025167A (ko) 2005-03-11
NL300920I2 (nl) 2021-04-15
CA2484420C (en) 2014-09-16
NL300920I1 (ja) 2018-01-03
AU2003223007C1 (en) 2019-08-08
US7919606B2 (en) 2011-04-05
SG161744A1 (en) 2010-06-29
SI1504035T1 (sl) 2010-07-30
EP1504035B8 (en) 2018-02-28
LUC00058I2 (ja) 2018-02-26
US20030235869A1 (en) 2003-12-25
NO336201B1 (no) 2015-06-15
CN100384878C (zh) 2008-04-30
EP1504035A2 (en) 2005-02-09
LUC00057I1 (ja) 2017-12-27
FR17C1062I2 (fr) 2020-05-29
EP1504035B3 (en) 2017-12-20
CO5631451A2 (es) 2006-04-28
NZ536757A (en) 2006-06-30
PL218433B1 (pl) 2014-12-31
LTC1504035I2 (lt) 2022-04-11
US20210371547A1 (en) 2021-12-02
LTPA2017043I1 (lt) 2018-01-10
NO2017068I1 (no) 2017-12-21
TWI324161B (en) 2010-05-01
EP1504035B1 (en) 2010-03-31
PT1504035E (pt) 2010-06-07
US20120302739A1 (en) 2012-11-29
US20110165659A1 (en) 2011-07-07
LUC00058I1 (ja) 2017-12-27
UA92580C2 (ru) 2010-11-25
WO2003093320A2 (en) 2003-11-13
ZA200408851B (en) 2006-01-25
US8895714B2 (en) 2014-11-25
IL164923A (en) 2012-03-29
DK1504035T3 (da) 2010-06-07
AU2003223007A1 (en) 2003-11-17
CY1110134T1 (el) 2015-01-14
CY2017046I1 (el) 2018-12-12
KR101156796B1 (ko) 2012-06-21
ES2341708T7 (es) 2018-04-11
CN103172742A (zh) 2013-06-26
US7355011B2 (en) 2008-04-08
CA2484420A1 (en) 2003-11-13
JP2013230158A (ja) 2013-11-14
HUS1700055I1 (hu) 2018-07-30
LTPA2017044I1 (lt) 2018-01-10
JP2010022372A (ja) 2010-02-04
CN101134779A (zh) 2008-03-05
HK1071762A1 (en) 2005-07-29
DK1504035T6 (en) 2018-03-12
NO2017069I1 (no) 2017-12-21
CY2017046I2 (el) 2018-12-12
KR101386376B1 (ko) 2014-04-16
BE2017C068I2 (ja) 2022-08-09
US20170145114A1 (en) 2017-05-25
ATE462729T3 (de) 2010-04-15
LUC00057I2 (ja) 2018-02-26
RU2342401C2 (ru) 2008-12-27
GB0210121D0 (en) 2002-06-12
MXPA04010787A (es) 2005-03-07
JP5377173B2 (ja) 2013-12-25
CY2017045I1 (el) 2019-11-27
DE60331910D1 (de) 2010-05-12
JP2006506955A (ja) 2006-03-02
US20100021995A1 (en) 2010-01-28
JP5920934B2 (ja) 2016-05-18
TW200307690A (en) 2003-12-16
KR20120127513A (ko) 2012-11-21
NO336201B3 (no) 2015-06-15
KR101238970B1 (ko) 2013-03-04
NO20044742L (no) 2004-12-22
US20070059307A1 (en) 2007-03-15
JP4486494B2 (ja) 2010-06-23
KR20110004463A (ko) 2011-01-13
AU2003223007B2 (en) 2009-07-16
ES2341708T3 (es) 2010-06-25
HUS1700056I1 (hu) 2018-07-30
CN103172742B (zh) 2016-05-11
CN101134779B (zh) 2013-03-13
CY2017045I2 (el) 2019-11-27
IL164923A0 (en) 2005-12-18
PL373277A1 (en) 2005-08-22
ECSP045470A (es) 2005-01-28
US20160326247A1 (en) 2016-11-10
CN1662558A (zh) 2005-08-31
HK1186479A1 (zh) 2014-03-14
EP1504035B9 (en) 2018-10-17
RU2004135103A (ru) 2005-10-27

Similar Documents

Publication Publication Date Title
FR17C1062I1 (ja)
AP2092A (en) Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof.
GB0124317D0 (en) Biological products
RS80704A (en) ANTI- av?6.ANTIBODIES
WO2005034733A3 (en) Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia
TW200635946A (en) Binding proteins specific for human matriptase
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules